Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HOLX
stocks logo

HOLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
1.07B
+5.04%
1.094
+6.23%
1.05B
+4.63%
1.094
+6.22%
1.07B
+4.65%
1.154
+6.89%
Estimates Revision
The market is revising Upward the revenue expectations for Hologic, Inc. (HOLX) for FY2026, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by 12.13%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.41%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.85%
In Past 3 Month
Stock Price
Go Up
up Image
+12.13%
In Past 3 Month
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 79.22 USD with a low forecast of 76.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 79.22 USD with a low forecast of 76.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
10 Hold
0 Sell
Hold
Current: 74.860
sliders
Low
76.00
Averages
79.22
High
94.00
Current: 74.860
sliders
Low
76.00
Averages
79.22
High
94.00
BNP Paribas Exane
Outperform -> Neutral
downgrade
$79
2025-11-21
Reason
BNP Paribas Exane
Price Target
$79
2025-11-21
downgrade
Outperform -> Neutral
Reason
BNP Paribas Exane downgraded Hologic to Neutral from Outperform with a $79 price target.
Morgan Stanley
Equal Weight
maintain
$69 -> $76
2025-11-10
Reason
Morgan Stanley
Price Target
$69 -> $76
2025-11-10
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Hologic (HOLX) to $76 from $69 and keeps an Equal Weight rating on the shares after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The firm views the proposed acquisition price as "a fair valuation" and doesn't expect any barriers to the transaction closing in the first half of 2026, the analyst tells investors.
Mizuho
Outperform -> Neutral
downgrade
$78
2025-10-23
Reason
Mizuho
Price Target
$78
2025-10-23
downgrade
Outperform -> Neutral
Reason
Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.
Stephens
Stephens
Overweight -> Equal Weight
downgrade
$78 -> $76
2025-10-22
Reason
Stephens
Stephens
Price Target
$78 -> $76
2025-10-22
downgrade
Overweight -> Equal Weight
Reason
Stephens downgraded Hologic (HOLX) to Equal Weight from Overweight with a price target of $76, down from $78, after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The deal is in line with the firm's expectations and "seems fair based on our outlook," the analyst tells investors.
JPMorgan
Overweight -> Neutral
downgrade
$78
2025-10-21
Reason
JPMorgan
Price Target
$78
2025-10-21
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Hologic (HOLX) to Neutral from Overweight with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.
Raymond James
Andrew Cooper
Outperform -> Market Perform
downgrade
$79
2025-10-21
Reason
Raymond James
Andrew Cooper
Price Target
$79
2025-10-21
downgrade
Outperform -> Market Perform
Reason
Raymond James analyst Andrew Cooper downgraded Hologic (HOLX) to Market Perform from Outperform after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Hologic Inc (HOLX.O) is 16.42, compared to its 5-year average forward P/E of 17.63. For a more detailed relative valuation and DCF analysis to assess Hologic Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.63
Current PE
16.42
Overvalued PE
21.13
Undervalued PE
14.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
15.19
Undervalued EV/EBITDA
10.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.27
Current PS
0.00
Overvalued PS
4.80
Undervalued PS
3.73
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 4616.24% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

HOLX News & Events

Events Timeline

(ET)
2025-11-03
16:03:00
Hologic announces Q4 adjusted EPS of $1.13, surpassing consensus estimate of $1.10
select
2025-11-03
14:28:13
Prominent Companies Set to Report After Market Close
select
2025-10-21 (ET)
2025-10-21
08:51:49
Blackstone to Acquire Hologic for $18.3 Billion
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-27NASDAQ.COM
HOLX vs. DGX: Which Healthcare Diagnostics Stock Offers a Better Investment Opportunity?

  • Hologic and Quest Diagnostics Overview: Hologic specializes in women's health diagnostics, while Quest Diagnostics offers a broader range of affordable testing services across the healthcare ecosystem. Year-to-date, Hologic shares have increased by 3.7%, whereas Quest Diagnostics shares have surged by 25.7%.

  • Hologic's Growth Drivers: Hologic's growth is supported by strong sales in breast health, international market expansion for GYN surgical products, and resilience in molecular diagnostics, including new FDA-approved assays and a focus on the vaginitis market.

  • Quest Diagnostics' Strategic Initiatives: Quest Diagnostics is enhancing its Advanced Diagnostics portfolio, with significant demand for tests like the AD-Detect for Alzheimer's. The company is also pursuing an aggressive acquisition strategy and operational excellence through its Invigorate program, targeting cost savings and productivity improvements.

  • Investment Outlook: Both companies hold a Zacks Rank #3 (Hold), with Quest Diagnostics appearing to be the more attractive investment option due to its impressive year-to-date performance and lower valuation compared to Hologic.

[object Object]
Preview
9.0
11-26NASDAQ.COM
Recent Clinical Findings Support Hologic's Breast Cancer Innovations

  • AI in Mammography: The global AI in breast imaging market is projected to grow at a CAGR of 3.30% through 2034, driven by rising breast cancer rates and technological advancements, with Hologic presenting new data on its AI technologies at the RSNA 2025 Annual Meeting.

  • Hologic's Innovations: Hologic's 3DQuorum imaging technology has shown potential to streamline radiologists' workflows without compromising cancer detection rates, while its Genius AIDetection solution performed comparably to radiologists in detecting cancers, albeit with lower specificity.

  • New Developments in Healthcare Technology: QIAGEN introduced the QIAsymphony Connect for automated nucleic acid purification, and GE Healthcare launched the Genesis Radiology Workspace to enhance radiology workflows and patient care.

  • Investment Insights: The AI sector is expected to create significant wealth, with a shift from the initial wave of AI stocks to emerging companies poised for growth, as highlighted in Zacks' report on the next phase of the AI boom.

[object Object]
Preview
7.0
11-22Globenewswire
Halper Sadeh LLC Urges FRGE, BHF, and HOLX Shareholders to Reach Out for Rights Consultation

  • Investigation of Companies: Halper Sadeh LLC is investigating Forge Global Holdings, Brighthouse Financial, and Hologic for potential violations of federal securities laws and breaches of fiduciary duties related to their sales to other corporations.

  • Details of Transactions: Forge is being sold for $45.00 per share, Brighthouse for $70.00 per share, and Hologic for $76.00 per share plus contingent value rights.

  • Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding the proposed transactions.

  • Contingent Fee Basis: The firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal fees unless the case is successful.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Hologic Inc (HOLX) stock price today?

The current price of HOLX is 74.86 USD — it has decreased -0.2 % in the last trading day.

arrow icon

What is Hologic Inc (HOLX)'s business?

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

arrow icon

What is the price predicton of HOLX Stock?

Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 79.22 USD with a low forecast of 76.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Hologic Inc (HOLX)'s revenue for the last quarter?

Hologic Inc revenue for the last quarter amounts to 1.05B USD, increased 6.23 % YoY.

arrow icon

What is Hologic Inc (HOLX)'s earnings per share (EPS) for the last quarter?

Hologic Inc. EPS for the last quarter amounts to 0.83 USD, increased 9.21 % YoY.

arrow icon

What changes have occurred in the market's expectations for Hologic Inc (HOLX)'s fundamentals?

The market is revising Upward the revenue expectations for Hologic, Inc. (HOLX) for FY2026, with the revenue forecasts being adjusted by 0.41% over the past three months. During the same period, the stock price has changed by 12.13%.
arrow icon

How many employees does Hologic Inc (HOLX). have?

Hologic Inc (HOLX) has 7070 emplpoyees as of December 05 2025.

arrow icon

What is Hologic Inc (HOLX) market cap?

Today HOLX has the market capitalization of 16.69B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free